Degli Esposti Luca, Saragoni Stefania, Buda Stefano, Sturani Alessandra, Degli Esposti Ezio
CliCon Srl, Health, Economics and Outcomes Research, Ravenna, Italy.
Clinicoecon Outcomes Res. 2013 May 14;5:193-201. doi: 10.2147/CEOR.S41846. Print 2013.
Diabetes is one of the most prevalent chronic diseases, and its prevalence is predicted to increase in the next two decades. Diabetes imposes a staggering financial burden on the health care system, so information about the costs and experiences of collecting and reporting quality measures of data is vital for practices deciding whether to adopt quality improvements or monitor existing initiatives. The aim of this study was to quantify the association between health care costs and level of glycemic control in patients with type 2 diabetes using clinical and administrative databases.
A retrospective analysis using a large administrative database and a clinical registry containing laboratory results was performed. Patients were subdivided according to their glycated hemoglobin level. Multivariate analyses were used to control for differences in potential confounding factors, including age, gender, Charlson comorbidity index, presence of dyslipidemia, hypertension, or cardiovascular disease, and degree of adherence with antidiabetic drugs among the study groups.
Of the total population of 700,000 subjects, 31,022 were identified as being diabetic (4.4% of the entire population). Of these, 21,586 met the study inclusion criteria. In total, 31.5% of patients had very poor glycemic control and 25.7% had excellent control. Over 2 years, the mean diabetes-related cost per person was: €1291.56 in patients with excellent control; €1545.99 in those with good control; €1584.07 in those with fair control; €1839.42 in those with poor control; and €1894.80 in those with very poor control. After adjustment, compared with the group having excellent control, the estimated excess cost per person associated with the groups with good control, fair control, poor control, and very poor control was €219.28, €264.65, €513.18, and €564.79, respectively.
Many patients showed suboptimal glycemic control. Lower levels of glycated hemoglobin were associated with lower diabetes-related health care costs. Integration of administrative databases and a laboratory database appears to be suitable for showing that appropriate management of diabetes can help to achieve better resource allocation.
糖尿病是最常见的慢性病之一,预计在未来二十年其患病率还会上升。糖尿病给医疗保健系统带来了惊人的经济负担,因此,对于决定是否采用质量改进措施或监测现有举措的医疗机构而言,有关收集和报告数据质量指标的成本及经验的信息至关重要。本研究旨在利用临床和管理数据库,量化2型糖尿病患者的医疗保健成本与血糖控制水平之间的关联。
利用一个大型管理数据库和一个包含实验室检查结果的临床登记系统进行回顾性分析。患者根据糖化血红蛋白水平进行分组。采用多变量分析来控制潜在混杂因素的差异,这些因素包括年龄、性别、查尔森合并症指数、血脂异常、高血压或心血管疾病的存在情况,以及研究组中抗糖尿病药物的依从程度。
在70万研究对象中,有31022人被确定为糖尿病患者(占总人数的4.4%)。其中,21586人符合研究纳入标准。总体而言,31.5%的患者血糖控制非常差,25.7%的患者血糖控制良好。在两年时间里,每人与糖尿病相关的平均费用为:血糖控制良好的患者为1291.56欧元;控制较好的患者为1545.99欧元;控制一般的患者为1584.07欧元;控制较差的患者为1839.42欧元;控制非常差的患者为1894.80欧元。调整后,与血糖控制良好的组相比,血糖控制较好、一般、较差和非常差的组每人估计的额外费用分别为219.28欧元、264.65欧元、513.18欧元和564.79欧元。
许多患者的血糖控制未达最佳水平。糖化血红蛋白水平较低与糖尿病相关的医疗保健成本较低相关。管理数据库和实验室数据库的整合似乎适合用于表明,对糖尿病进行适当管理有助于实现更好的资源分配。